Accelerating Your BioTech Idea – Blavatnik Fund and ABCT Program Info Session

The Blavatnik Fund for Innovation at Yale supports Yale faculty in the commercialization of applied research and technology in the life sciences. A significant obstacle to the development of early-stage university discoveries is the lack of funding for the proof-of-concept and validation studies needed to demonstrate commercial potential. To overcome this barrier, the Fund provides funding and business development support to help validate nascent technologies and identify potential industry partners to advance these technologies to the marketplace.

The Fund seeks to support innovative, investigator-initiated research aimed at extending preliminary observations, with proof-of-concept and the generation of robust intellectual property as key objectives. The Fund is designed to accommodate projects of varying magnitude, as appropriate. Its primary goal is to advance technologies to the point where additional support from industry and/or technology transfer is achieved.

Supported projects may include such areas as therapeutics, diagnostics/biomarkers, medical devices, or research instruments, among others. The expected goal of completed projects will be partnerships with industry, through licenses to existing biopharmaceutical companies and startup firms (some launched from the Fund-supported technology) or via major industry-sponsored research agreements. It is expected that these alliances will lead to additional industry-sponsored research support. The Fund is structured as a sustainable, “evergreen” program. Twenty percent of the revenue from successfully licensed technologies will be contributed back to the Blavatnik Fund for Innovation at Yale to support ongoing and future projects.

Applications for the Blavatnik Fund for Innovation at Yale will open October 1, 2019, and will be accepted up until 5pm on Oct 28, 2019

Accelerator for Biosciences in Connecticut, ABCT, is a competitive entry, 6-month long program designed for entrepreneurial research students and faculty, MBA’s and MD’s interested to form new ventures in biosciences. ABCT encourages applications from IP based inventions. Operated in CT and NYC, ABCT connects emerging ventures, corporate supporters, academics, and capital in CT and NYC. ABCT ventures include therapeutics, diagnostics, devices, research tools, digital health and materials technology breakthroughs. Yale affiliated ABCT ventures include Cytosolix, EliV5, Krouzon, and MEaDvise. You do not need a company formed to apply to ABCT.

Join us, along with ABCT alums John Deacon and Choukri Ben Mamoun, to learn about the program, hear about their experience, and have your questions answered!

For more information please go to www.ABCT.co. To apply: https://abct.co/apply/application-form/. Application Deadline October 22, 2019.